# DESCRIPTION

- introduce treatment approach

## BACKGROUND OF THE INVENTION

- define itch
- describe urgent need to scratch
- discuss impact on quality of life
- introduce chronic itch cycle
- describe skin barrier damage
- mention itch-associated diseases
- discuss limitations of anti-histamine drugs
- introduce non-histaminergic pathways
- highlight IL-31 as novel target molecule
- describe IL-31's skin tropism
- discuss IL-31's role in atopic dermatitis
- introduce pain as another neurological sensation
- define pain
- discuss classification of chronic pain
- describe mechanical allodynia
- discuss impact on quality of life
- introduce need for specific treatment
- discuss spinal circuits and mechanical pain
- introduce A-fibre mechanoreceptors
- discuss role of A-fibre mechanoreceptors in pain
- introduce problem of adverse neurological sensations
- describe need for therapeutic strategy
- introduce method for targeting and inhibiting/killing target cells
- describe conjugate compound
- discuss binding domain and photosensitive inhibition/cytotoxin group
- describe administration of conjugate compound
- discuss irradiation of target body surface area
- introduce conjugate compound for use in method
- discuss treatment of neurological sensations
- describe target cell and target body surface area
- introduce TrkB, TrkA, IL31RA, and OSMR as target cells
- discuss neurological sensations and target cells
- define itch and pruritus
- discuss itch related disorders or diseases
- introduce patient to be treated
- discuss treatment of non-human mammals
- describe types of itch
- introduce pain as neurological sensation
- discuss types of pain
- describe mechanical allodynia
- discuss treatment of mechanical allodynia
- introduce background of invention
- define sensory neuron
- describe conjugate compound
- define antibody
- describe humanized antibodies
- describe transgenic animals
- describe display technologies
- describe aglycosylated antibody
- describe antibody fragments
- describe target cell
- describe receptor
- describe inactivating target cell
- describe photosensitive inhibition/cytotoxin group
- describe cytotoxic agent
- describe therapeutic groups
- describe chemotherapeutic groups
- describe photosensitizing agent
- describe beneficial effect of method
- describe alleviating neurological sensation
- define pruritogen
- describe IL31
- describe mutant IL31
- describe conjugate compound with IL31
- describe SNAP tag
- describe TrkB gene
- describe TrkB protein
- describe TrkB ligand
- describe anti-TrkB antibody
- describe TrkB T cell receptor
- describe chimeric antigen receptor
- describe nucleic acid sequence
- describe BDNF
- describe NT-4
- describe TrkA gene
- describe TrkA protein
- describe TrkA RNA
- describe TrkA ligand
- describe anti-TrkA antibody
- describe TrkA T cell receptor
- describe chimeric antigen receptor
- describe NGF
- describe NGFR121W mutant

## Diseases, Treatments and Pharmaceutical Compositions

- define subject
- describe diseases
- specify preferred embodiments
- describe itch
- describe itch associated diseases
- describe treatment
- describe administration
- define systemic administration
- define local administration
- describe pharmaceutical compositions
- describe conjugate compound
- describe target body surface area
- describe method of treatment
- describe illumination
- describe neuronal retraction
- describe pharmaceutical composition
- describe dosage
- describe dosage determination
- describe factors affecting dosage
- describe physician's role
- introduce item 1
- describe compound for use
- describe binding to TrkB
- describe functional moiety
- describe pharmaceutical composition

## EXAMPLES

### I: ITCHING

- generate IL31SNAP
- characterize IL31SNAP
- perform binding studies
- examine IL31SNAP labelling in vivo
- determine IL31SNAP activity
- motivate IL31 mediated photoablation
- synthesize IR700
- conjugate IR700 to IL31SNAP
- apply IL31SNAP-IR700 to keratinocytes
- provoke cell death
- examine photosensitizer induced cell death in skin
- impact on IL31 evoked scratching behavior
- generate IL31K138A-SNAP
- characterize IL31K138A-SNAP
- examine IL31K138A-SNAP labelling
- assess cellular signaling pathways
- test IL31K138A-SNAP capacity to provoke scratching
- characterize IL31K138A-SNAP mediated photoablation
- alleviate IL31 provoked itch
- test effects on other acutely applied pruritogens
- assess specificity of photoablation
- examine effects on chronic inflammatory itch
- prevent Calcipotriol provoked dermatitis
- reverse established skin inflammation
- develop topical formulation
- apply IL31K138A-SNAP-IR700 topically
- prevent and reverse Calcipotriol provoked dermatitis
- normalize skin structure and histology
- demonstrate specificity for IL31RA expressing cells
- describe animal model
- describe production of recombinant IL31SNAP and IL31K138A-SNAP
- describe synthesis of BG-IR700
- describe primary keratinocyte culture
- describe in-vitro and in-vivo labeling
- describe in-vitro photo-ablation
- describe in-vivo photo-ablation
- describe microemulsion preparation
- describe statistical analysis

### II: PAIN

- introduce TrkB positive neurons
- characterize response properties
- ablate TrkB positive neurons
- examine behavioral responses
- test optogenetic activation
- induce inflammatory pain
- ablate TrkB neurons in inflammatory pain
- test optogenetic activation in inflammatory pain
- induce neuropathic pain
- ablate TrkB neurons in neuropathic pain
- test optogenetic activation in neuropathic pain
- examine C-fos induction
- develop pharmacological strategy
- produce recombinant BDNF protein
- test BDNF selectivity
- apply BDNF to DRG neurons
- manipulate TrkB neurons in vivo
- synthesize benzylguanine modified IR700
- conjugate IR700 to BDNF
- test BDNF-IR700 in HEK293T cells
- test BDNF-IR700 in wildtype mice
- examine effects on mechanical allodynia
- examine effects on other types of neuropathic pain
- assess selectivity of approach
- investigate mechanism of BDNF-IR700
- examine innervation density of hypersensitive skin
- examine loss of TrkB fibers
- examine loss of TrkB neurons
- identify TrkB expressing cells in skin
- ablate TrkB sensory fibers
- examine behavioral responses
- introduce NGF to target nociceptive sensory neurons
- produce recombinant NGFSNAP protein
- test NGFSNAP selectivity
- conjugate IR700 to NGFSNAP
- test NGFSNAP-IR700 in inflammatory pain
- test NGFSNAP-IR700 in acute pain

